Brief: Carsgen Therapeutics Sees FY Net Loss Of Up To RMB120 MLN
26/01/2026 10:31
Jan 26 (Reuters) - CARsgen Therapeutics Holdings Ltd 2171.HK: NET LOSS EXPECTED TO REDUCE TO UP TO RMB120 MILLION IN FY LOSS REDUCTION DUE TO INCREASED REVENUES FROM ZEVORCABTAGENE AUTOLEUCEL, OTHERS IN FY Further company coverage: 2171.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on CARsgen Therapeutics Holdings
See all newsBrief: Carsgen Therapeutics Says CT1190B Receives IND Clearance From NMPA For Relapsed/Refractory Large B-Cell Lymphoma
Brief: Carsgen Therapeutics Says CT0596 Receives IND Clearance From NMPA
Brief: Carsgen Therapeutics Approves Share Repurchase Plan For Up To 30.12 Million Shares
CARsgen Therapeutics climbs on board nod for share buyback
Brief: Carsgen Therapeutics Says NMPA Approves Satricabtagene Autoleucel For Advanced Gastric Cancer